A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab.

被引：0
作者：
Takahashi, Naoki
Iwasa, Satoru
Tachikawa, Masanori
Fukahori, Masaru
Sudo, Kazuki
Sasaki, Yusuke
Shoji, Hirokazu
Honma, Yoshitaka
Okita, Natsuko
Takashima, Atsuo
Hamaguchi, Tetsuya
Boku, Narikazu
Shimada, Yasuhiro
Yamagiwa, Koki
Ebata, Yuka
Uchida, Yasuo
Honda, Kazufumi
Terasaki, Tetsuya
Yamada, Yasuhide
机构：
[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan
[2] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan
[3] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, Fukuoka, Japan
[4] Natl Canc Ctr, 1-1 Tsukiji 5 chome, Tokyo, Japan
[5] Natl Canc Ctr, Chuo Ku, 1-1 Tsukiji 5 chome, Tokyo, Japan
[6] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan
[7] Natl Canc Ctr, Res Inst, Tokyo 104, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.759
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
759
引用
收藏
页数：1
相关论文
共 50 条
[21]   COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN [J].
Barbosa, Caroline ;
Sousa, Romulado ;
Sabbaga, Jorge ;
Cotti, Guilherme ;
Saragiotto, Daniel ;
Hoff, Paulo .
ANNALS OF ONCOLOGY, 2011, 22 :v103-v103
[22]   Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer [J].
Yamaguchi, Toshifumi ;
Iwasa, Satoru ;
Nagashima, Kengo ;
Ikezawa, Nobuaki ;
Hamaguchi, Tetsuya ;
Shoji, Hirokazu ;
Honma, Yoshitaka ;
Takashima, Atsuo ;
Okita, Natsuko ;
Kato, Ken ;
Yamada, Yasuhide ;
Shimada, Yasuhiro .
ANTICANCER RESEARCH, 2016, 36 (07) :3531-3536
[23]   A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients [J].
Elena Elez ;
Carles Pericay ;
Manuel Valladares-Ayerbes ;
Inmaculada Bando ;
Maria Jose Safont ;
Javier Gallego ;
Cristina Grávalos ;
Antonio Arrivi ;
Alfredo Carrato ;
Verónica Conde ;
Maria José Ortiz ;
Carlos López ;
Beatriz Alonso ;
Inmaculada Ruiz de Mena ;
Eduardo Díaz-Rubio ;
Josep Tabernero ;
Enrique Aranda .
British Journal of Cancer, 2019, 121 :378-383
[24]   A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients [J].
Elez, Elena ;
Pericay, Caries ;
Valladares-Ayerbes, Manuel ;
Bando, Inmaculada ;
Safont, Maria Jose ;
Gallego, Javier ;
Gravalos, Cristina ;
Arrivi, Antonio ;
Carrato, Alfredo ;
Conde, Veronica ;
Jose Ortiz, Maria ;
Lopez, Carlos ;
Alonso, Beatriz ;
Ruiz de Mena, Inmaculada ;
Diaz-Rubio, Eduardo ;
Tabernero, Josep ;
Aranda, Enrique .
BRITISH JOURNAL OF CANCER, 2019, 121 (05) :378-383
[25]   Phase II study of combination therapy with S-1 and cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901). [J].
Kobayashi, Kazuma ;
Emi, Yasunori ;
Kakeji, Yoshihiro ;
Takahashi, Takao ;
Oki, Eiji ;
Akagi, Yoshito ;
Tsuji, Akihito ;
Kodera, Yasuhiro ;
Yoshida, Kazuhiro ;
Baba, Hideo ;
Shimada, Mitsuo ;
Ogata, Yutaka ;
Shimokawa, Mototsugu ;
Tokunaga, Shoji ;
Natsugoe, Shoji ;
Maehara, Yoshihiko .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[26]   Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients [J].
Terazawa, Tetsuji ;
Nishitani, Hitoshi ;
Kato, Ken ;
Hashimoto, Hironobu ;
Akiyoshi, Kohei ;
Ito, Yuriko ;
Nakamoto, Akihiro ;
Iwasa, Satoru ;
Nakajima, Takako Eguchi ;
Hamaguchi, Tetsuya ;
Yamada, Yasuhide ;
Shimada, Yasuhiro .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) :E132-E137
[27]   Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study [J].
Chibaudel, B. ;
Tournigand, C. ;
Mabro, M. ;
Bennamoun, M. ;
Artru, P. ;
Nguyen, S. ;
Bachet, J. ;
Aissat, N. ;
Blons, H. ;
Laurent-Puig, P. ;
De Gramont, A. ;
Andre, T. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[28]   PHASE II STUDY OF COMBINATION THERAPY WITH S-1 AND CETUXIMAB IN PATIENTS WITH KRAS WILD-TYPE UNRESECTABLE COLORECTAL CANCER, WHO HAD PREVIOUSLY RECEIVED IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES (KSCC0901) [J].
Kitazono, M. ;
Kobayashi, K. ;
Emi, Y. ;
Kakechi, Y. ;
Takahashi, T. ;
Akagi, Y. ;
Tuji, A. ;
Yoshida, K. ;
Baba, H. ;
Ogata, H. ;
Shimokawa, M. ;
Natsugoe, S. ;
Maehara, Y. .
ANNALS OF ONCOLOGY, 2012, 23 :122-122
[29]   Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study [J].
Andre, T. ;
Chibaudel, B. ;
Mabro, M. ;
Bennamoun, M. ;
Artru, P. ;
Bachet, J. B. ;
Hadengue, A. ;
Blons, H. ;
Laurent-Puig, P. ;
de Gramont, A. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 :S435-S435
[30]   Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181 [J].
Price, T. ;
Peeters, M. ;
Strickland, A. ;
Ciuleanu, T. E. ;
Scheithauer, W. ;
O'Reilly, S. ;
Keane, M. ;
Spigel, D. ;
Tian, Y. ;
Kartik, K. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 :S431-S432
12345